With a focus on research and development in the area of innovative medicines, this STOA study discusses a new European approach to pharmaceutical policy. After examining the European pharmaceutical sector's features, and the strengths and weaknesses of the current research and business model, the study explores the need for and the concept of a European infrastructure with a long-term transboundary mission. The study is based on an extensive literature review and a targeted survey of international experts from science, industry, public health, and government institutions. The survey investigated the feasibility of different options in terms of the scope of the mission and legal, organisational, and financial arrangements for establishing such a European infrastructure. The study concludes by presenting a range of policy options.
Professor Massimo Florio presented the study during a STOA panel meeting at the European Parliament.